| Document |
Document Title |
|
WO/1998/032718A1 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
WO/1998/032763A1 |
Novel compounds useful as inhibitors of estrone sulfatase are provided. The compounds have structural formula (I), wherein X and Y, or Y and Z, form an oxathiazine dioxide ring or a dihydro-oxathiazine dioxide ring, and the other various...
|
|
WO/1998/031702A1 |
The present invention relates to 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives according to formula (I), wherein R�1? is C�1-6?alkyl, C�3-6?cycloalkyl, C�1-6?alkoxy, triflate, pyridyl or phenyl where the phenyl m...
|
|
WO/1998/025948A2 |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of formula (I) wherein: -A-A- represents the group -CHR?4�-CHR?5�- or -CR?4�=CR?5�-...
|
|
WO/1998/018813A1 |
Methods for preparing intermediates for 21-alkylated corticosteroids are discloded. Pregna-1,4,16-trien-3,20-diones are contacted with a base and an alkylating agent to produce corresponding 21-alkylated pregna-1,4,16-trien-3,20-diones.
|
|
WO/1998/014194A1 |
The invention relates to a method of alleviating the symptoms of anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The st...
|
|
WO/1998/009982A1 |
The invention describes a process for epimer enrichment of compounds of formula (I) where R?1�1 and R?2� are as defined in the description, by fractional crystallization.
|
|
WO/1998/007741A1 |
The present invention pertains to a process for producing eltanolone (I), wherein epi-sarsasapogenine (II) is broken down in the presence of ammomium chloride and pyridine and acetane hydride to obtain 3$g(a), 26-diacetoxy-5$g(b), 25S-fu...
|
|
WO/1998/004577A1 |
A process is disclosed for preparing 16$g(a)-hydroxy-estra-1,3,5(10)-triene derivatives having the general formula (I), in which R�1? stands for a hydrogen atom, an alkyl group with maximum 4 carbon atoms, a benzyl group or an acyl gro...
|
|
WO/1998/003207A1 |
The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor...
|
|
WO/1998/002450A2 |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
WO/1998/000437A1 |
The invention provides an improved process for the preparation of 17-esters of 9$g(a),21-dihalo-pregnane-11$g(b),17$g(a)-diol-20-ones, and in particular for the preparation of 17-esters of anti-inflammatory steroids according to the abov...
|
|
WO/1998/000397A1 |
A crystal of the compound of the structural formula (I); crystals of vitamin D derivatives prepared by purifying unpurified or roughly purified vitamin D derivatives by reversed phase chromatography and crystallizing the purified derivat...
|
|
WO/1997/041145A1 |
A compound having general formula (I) in which R1 is a member selected from the group consisting of -OCH3, -SCH3, -N(CH3)2, -NHCH3, -CHO, -COCH3 and -CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hyd...
|
|
WO/1997/041144A1 |
The present invention relates to a compound having the formula A-B-C, wherein A is a hydroxyl containing steroidal hormone; C is a nitrite or nitrate containing compound; and B is lower alkyl, lower alkenyl, lower alkynyl, and to pharmac...
|
|
WO/1997/036596A1 |
The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithel...
|
|
WO/1997/034871A1 |
Disclosed are (i) compounds of a steroid, a 'beta'-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous prod...
|
|
WO/1997/031014A1 |
Triterpene derivatives efficacious in the treatment of liver diseases. The remedies contain as the active ingredient triterpene derivatives represented by general formula (I) or salts thereof: wherein R1 represents hydroxy, arylmethyloxy...
|
|
WO/1997/030068A1 |
Process for preparing the compound 11'beta'-21-dihydroxy-2'-methyl-5''beta'H-pregna-1,4-dieno[1
7,16-d-]-oxazoline-3,20-dione of formula (I), which comprises adsorbing said compound, contained into an aqueous solution resulting from ferm...
|
|
WO/1997/027210A1 |
The invention relates to compounds of formula (I), in which R1, R2, R3, R4, R5, R6, n and X are as defined in the specification, and to pharmaceutical compositions containing them. These compounds are excellent progestogens which are dev...
|
|
WO/1997/024367A1 |
Compounds of the pregnane series are described having general formula (I) and solvates thereof in which R1 individually represents -OC(=O)C1-6 alkyl; R2 individually represents hydrogen, methyl (which may be in the 'alpha' or 'beta' conf...
|
|
WO/1997/024368A1 |
Compounds of the androstane series are described having general formula (I) and solvates thereof in which R1 and R2 are the same or different and each represents hydrogen or C1-6 alkyl; R3 and R4 are the same or different and each repres...
|
|
WO/1997/022616A1 |
Disclosed is a process for producing the epoxy steroid (1.0) wherein R1 is selected from H, -OH, or C1, and R2 is selected from hydrogen or lower alkyl. The process comprises reacting the triene of Formula (2.0) with a brominating or chl...
|
|
WO/1997/021723A1 |
A process for preparing the compound (11'beta',16'beta')-21-(3-carboxy-3-oxopropoxy)-11-hydroxy-2
'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione which comprises reacting the compound (11'beta',16'beta',-11,21-dihydroxy-2'-methy...
|
|
WO/1997/021720A2 |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of formula (I), wherein: -A-A- represents the group -CHR4-CHR5- or -CR4=CR5-; R3, R4 and R5...
|
|
WO/1997/021724A1 |
The present invention discloses novel steroid nitrite ester derivatives, and to their use treating inflammatory diseases.
|
|
WO/1997/021722A1 |
A process for preparing the compound (11'beta',16'beta')-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-
pregna-1,4-dieno[17,16-d]oxazole-3,20-dione (deflazacort) which comprises reacting (11'beta',16'beta')-11,21-dihydroxy-2'-methyl-5'H-pregna...
|
|
WO/1997/013780A1 |
The present invention relates to the biochemistry field, and in particular to the production of new spirostannic analogs of brasinoesteroids with oxygenated functions at different positions of the ring A from steroidal sapogenines, throu...
|
|
WO/1997/010256A1 |
Hitherto unknown compounds of formula (II) wherein R1 is hydrogen or methyl; R2 is hydrogen, methyl, CH2OH, CH2OR3, CHO, CH=CH2, COOH or COOR4; R3 is alkyl, aralkyl, aryl, alkanesulfonyl, arene-sulfonyl; alkanoyl or aroyl, optionally sub...
|
|
WO/1997/003088A1 |
A remedy for liver diseases which comprises a triterpene derivative represented by following general formula (I) or a pharmaceutically acceptable salt thereof wherein R1 represents hydroxy, alkoxy, alkylcarbonyloxy or aralkyloxy; R2 repr...
|
|
WO/1997/001346A1 |
A cosmetic or pharmaceutical and particularly dermatological composition including, as the active ingredient, an extract of plants of genus Filicium, and particularly an extract of plants of species Filicium decipiens, preferably in an a...
|
|
WO/1996/040727A1 |
The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor-pregnane steroid, or a pharmaceutical composition containing a vomerophe...
|
|
WO/1996/038466A1 |
The invention relates to certains steroidal glycoside derivatives useful as hypocholesterolemic agents and antiatherosclerosis agents. The present invention is also directed to pharmaceutical compositions comprising such derivatives and ...
|
|
WO/1996/031524A1 |
A process is described for the preparation of (20R)-16'alpha',17'alpha'-butylidenedioxy-6'alpha',9'alpha'-
difluoro-11'beta'-hydroxy-17'beta'-(methylthio)androst-4-en-
3-one comprising a six step synthesis from a compound of formula (I)....
|
|
WO/1996/030390A2 |
Methods for the preparation of the 19-norprogesterone of formula (I) and its intermediates, in crystalline and amorphous forms.
|
|
WO/1996/028166A1 |
An osteoporosis remedy and an osteogenesis accelerator each containing at least either mepitiostane or epitiostanol as the active ingredient and having an excellent therapeutic effect exceeding the known drugs.
|
|
WO/1996/026201A1 |
Certain benzopyran antiestrogens are disclosed for treating estrogen sensitive diseases such as breast cancer. Prodrug forms provide ease of manufacturing, good shelf life, and bioavailibility, and preferred stereoisomers are shown to be...
|
|
WO/1996/022973A1 |
A compound represented by general formula (I), wherein R1 and R2 are the same or different and each represents C1-4 alkyl; and R3 represents C1-7 alkoxy optionally substituted by hydroxy, halogeno, cyano, C1-4 alkoxy, amino or acylamino;...
|
|
WO/1996/020209A2 |
The invention concerns 14,17-C2-bridged steroids of general formula (I), wherein: R3 represents an oxygen atom, the hydroxy amino group or two hydrogen atoms; R6 represents either a hydrogen, fluorine, chlorine or bromine atom or a C1-C4...
|
|
WO/1996/017819A1 |
The object of the present invention is to provide asiatic acid derivatives (I), its pharmaceutically acceptable salts or esters. Asiatic acid, its trisaccharide asiaticoside and madecassic acid, extracted from Centella asiatica have been...
|
|
WO/1996/016978A1 |
A process is described for the preparation of a compound of formula (I) or a stereoisomeric compound thereof, in which the 1,2-position is saturated or is a double bond; X1 and X2 are each independently hydrogen or halogen; R1 is hydroge...
|
|
WO/1996/011711A1 |
A preparation of saponins of Quillaja saponaria, comprises fractions of Quil A having good adjuvant activity, low haemolytic activity and good ability to form immunostimulatory complexes (iscoms).
|
|
WO/1996/010032A1 |
The invention relates to estrene steroid, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. The figure...
|
|
WO/1996/010031A1 |
The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors.
|
|
WO/1996/006854A1 |
Highly crystalline forms of (3'beta',5'alpha',25R)-3-[('beta'-D-4",6"-bis-[2-fluoropheny
lcarbamoyl]cellobiosyl)oxy]-spirostan-12-one that are useful as hypocholesterolemic or antiatherosclerosis agents.
|
|
WO/1996/004296A1 |
The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a pregnane or cholane steroid, or a pharmaceutical composition containing a vomer...
|
|
WO/1996/000236A1 |
Hederagenin derivatives represented by general formula (1) and pharmaceutically acceptable salts thereof, and a medicinal composition containing the same as the active ingredient and being efficacious in treating nephritis, wherein R1 re...
|
|
WO/1995/030341A1 |
The invention provides a comestible product comprising a fenugreek saponin as an emulsifying agent therein, said fenugreek saponin comprising a mixture of glucosidic steroids having formula (Ia or Ib) wherein R1, R2 and R3 are H, CH3, H;...
|
|
WO/1995/027697A1 |
A compound represented by general formula (I) and an intermediate therefor, and a process for synthesizing the both, wherein R1 represents optionally hydroxylated C1-C10 alkyl; R2 represents hydrogen or hydroxy; and R3 represents hydroge...
|
|
WO/1995/026974A1 |
A progesterone compound represented by general formula (1) and a neovascularization inhibitor containing the same as the active ingredient (wherein R1 represents a C1-C23 hydrocarbon group). It has a potent neovascularization inhibitory ...
|
